JP2011144207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011144207A5 JP2011144207A5 JP2011100206A JP2011100206A JP2011144207A5 JP 2011144207 A5 JP2011144207 A5 JP 2011144207A5 JP 2011100206 A JP2011100206 A JP 2011100206A JP 2011100206 A JP2011100206 A JP 2011100206A JP 2011144207 A5 JP2011144207 A5 JP 2011144207A5
- Authority
- JP
- Japan
- Prior art keywords
- poly
- group
- agents
- organic
- naphthoate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012074 organic phase Substances 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 239000008346 aqueous phase Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 150000002500 ions Chemical class 0.000 claims description 17
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 14
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 10
- 108010016076 Octreotide Proteins 0.000 claims description 10
- 239000006184 cosolvent Substances 0.000 claims description 10
- 229960002700 octreotide Drugs 0.000 claims description 6
- 238000000034 method Methods 0.000 claims 60
- 230000000975 bioactive effect Effects 0.000 claims 15
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims 14
- 239000011859 microparticle Substances 0.000 claims 12
- 238000013270 controlled release Methods 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 239000000126 substance Substances 0.000 claims 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 9
- 238000004945 emulsification Methods 0.000 claims 9
- 239000003995 emulsifying agent Substances 0.000 claims 9
- -1 polyacetyls Polymers 0.000 claims 9
- 239000004632 polycaprolactone Substances 0.000 claims 9
- 229920001610 polycaprolactone Polymers 0.000 claims 9
- 229920001223 polyethylene glycol Polymers 0.000 claims 9
- 229920000642 polymer Polymers 0.000 claims 9
- 229940080296 2-naphthalenesulfonate Drugs 0.000 claims 7
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 claims 7
- 108010000817 Leuprolide Proteins 0.000 claims 7
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical group CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 7
- 229960004338 leuprorelin Drugs 0.000 claims 7
- 238000002156 mixing Methods 0.000 claims 7
- KHARCSTZAGNHOT-UHFFFAOYSA-L naphthalene-2,3-dicarboxylate Chemical compound C1=CC=C2C=C(C([O-])=O)C(C(=O)[O-])=CC2=C1 KHARCSTZAGNHOT-UHFFFAOYSA-L 0.000 claims 7
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 229960000953 salsalate Drugs 0.000 claims 7
- UOBYKYZJUGYBDK-UHFFFAOYSA-M 2-naphthoate Chemical compound C1=CC=CC2=CC(C(=O)[O-])=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-M 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 6
- 229920001710 Polyorthoester Polymers 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 239000002105 nanoparticle Substances 0.000 claims 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 6
- WILNLXGNKANPKN-UHFFFAOYSA-N trifluoromethyl 4-methylbenzoate Chemical compound CC1=CC=C(C(=O)OC(F)(F)F)C=C1 WILNLXGNKANPKN-UHFFFAOYSA-N 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 claims 5
- 150000003384 small molecules Chemical class 0.000 claims 5
- DSZOEVVLZMNAEH-BXUJZNQYSA-N acetic acid;(2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2s)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoe Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 DSZOEVVLZMNAEH-BXUJZNQYSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229960001494 octreotide acetate Drugs 0.000 claims 4
- 229940062856 oxytocin acetate Drugs 0.000 claims 4
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 101800000989 Oxytocin Proteins 0.000 claims 3
- 102400000050 Oxytocin Human genes 0.000 claims 3
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims 3
- 229920002732 Polyanhydride Polymers 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 229920000954 Polyglycolide Polymers 0.000 claims 3
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 3
- 229940050528 albumin Drugs 0.000 claims 3
- 229940035676 analgesics Drugs 0.000 claims 3
- 229940035674 anesthetics Drugs 0.000 claims 3
- 239000000730 antalgic agent Substances 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 230000003474 anti-emetic effect Effects 0.000 claims 3
- 230000002921 anti-spasmodic effect Effects 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 239000003146 anticoagulant agent Substances 0.000 claims 3
- 229940127219 anticoagulant drug Drugs 0.000 claims 3
- 239000003472 antidiabetic agent Substances 0.000 claims 3
- 229940125708 antidiabetic agent Drugs 0.000 claims 3
- 229940125683 antiemetic agent Drugs 0.000 claims 3
- 239000002111 antiemetic agent Substances 0.000 claims 3
- 239000003429 antifungal agent Substances 0.000 claims 3
- 229940121375 antifungal agent Drugs 0.000 claims 3
- 229940125715 antihistaminic agent Drugs 0.000 claims 3
- 239000000739 antihistaminic agent Substances 0.000 claims 3
- 239000002220 antihypertensive agent Substances 0.000 claims 3
- 229940030600 antihypertensive agent Drugs 0.000 claims 3
- 229960005475 antiinfective agent Drugs 0.000 claims 3
- 239000003430 antimalarial agent Substances 0.000 claims 3
- 229940033495 antimalarials Drugs 0.000 claims 3
- 239000004599 antimicrobial Substances 0.000 claims 3
- 239000000164 antipsychotic agent Substances 0.000 claims 3
- 229940124575 antispasmodic agent Drugs 0.000 claims 3
- 239000003443 antiviral agent Substances 0.000 claims 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims 3
- 239000012867 bioactive agent Substances 0.000 claims 3
- 229940125692 cardiovascular agent Drugs 0.000 claims 3
- 239000002327 cardiovascular agent Substances 0.000 claims 3
- 230000015556 catabolic process Effects 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 238000006731 degradation reaction Methods 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- 235000019441 ethanol Nutrition 0.000 claims 3
- 239000003193 general anesthetic agent Substances 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 239000000787 lecithin Substances 0.000 claims 3
- 229940067606 lecithin Drugs 0.000 claims 3
- 235000010445 lecithin Nutrition 0.000 claims 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 3
- 229960001723 oxytocin Drugs 0.000 claims 3
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 3
- 229920001308 poly(aminoacid) Polymers 0.000 claims 3
- 229920000117 poly(dioxanone) Polymers 0.000 claims 3
- 229940065514 poly(lactide) Drugs 0.000 claims 3
- 229920000515 polycarbonate Polymers 0.000 claims 3
- 239000004417 polycarbonate Substances 0.000 claims 3
- 229920002721 polycyanoacrylate Polymers 0.000 claims 3
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims 3
- 229920000136 polysorbate Polymers 0.000 claims 3
- 229950008882 polysorbate Drugs 0.000 claims 3
- 239000004814 polyurethane Substances 0.000 claims 3
- 229920002635 polyurethane Polymers 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 150000003431 steroids Chemical class 0.000 claims 3
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims 3
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 claims 2
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 3
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 2
- 238000000710 polymer precipitation Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48766303P | 2003-07-15 | 2003-07-15 | |
| US60/487,663 | 2003-07-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006520347A Division JP5165239B2 (ja) | 2003-07-15 | 2004-07-15 | 制御放出処方物の調製のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011144207A JP2011144207A (ja) | 2011-07-28 |
| JP2011144207A5 true JP2011144207A5 (cg-RX-API-DMAC7.html) | 2013-06-06 |
Family
ID=34102710
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006520347A Expired - Fee Related JP5165239B2 (ja) | 2003-07-15 | 2004-07-15 | 制御放出処方物の調製のための方法 |
| JP2011100206A Pending JP2011144207A (ja) | 2003-07-15 | 2011-04-27 | 制御放出処方物の調製のための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006520347A Expired - Fee Related JP5165239B2 (ja) | 2003-07-15 | 2004-07-15 | 制御放出処方物の調製のための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8871269B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1651136B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5165239B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN1852687B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004259208B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0412059A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2532302C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2625343T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005009356A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2427092T3 (es) | 2003-04-10 | 2013-10-28 | Evonik Corporation | Un método para la producción de micropartículas a base de emulsión |
| US20070207211A1 (en) * | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
| WO2005009356A2 (en) | 2003-07-15 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Method for the preparation of controlled release formulations |
| EP1660039B1 (en) * | 2003-07-18 | 2016-09-28 | Oakwood Laboratories L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| EP2444069B1 (en) * | 2003-07-23 | 2019-06-05 | Evonik Corporation | Controlled release compositions |
| AU2004313245B2 (en) * | 2003-12-30 | 2011-04-14 | Durect Corporation | Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH |
| EP1679065A1 (en) * | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
| US20100290982A1 (en) * | 2007-04-13 | 2010-11-18 | University Of North Texas Health Science Center At Fort Worth | Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles |
| MX2009010907A (es) * | 2007-04-13 | 2010-03-17 | Univ North Texas | Formulacion del agente activo cargado en nanoparticulas de plga activadas para nano-terapeuticos direccionados para el cancer. |
| EP2139458A4 (en) * | 2007-04-19 | 2013-01-23 | Dong A Pharm Co Ltd | COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA |
| GB0709322D0 (en) * | 2007-05-15 | 2007-06-20 | Nordic Bioscience As | Exposure agent for detection of vitamin d |
| WO2008145183A1 (en) * | 2007-05-30 | 2008-12-04 | Nestec S.A. | Oil-in-water emulsion and its use for the delayed release of active elements |
| AU2008310956B2 (en) | 2007-10-08 | 2014-08-07 | Aurinia Pharmaceuticals Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors |
| ES2324009B1 (es) * | 2007-11-23 | 2010-05-21 | Gp Pharm S.A. | Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo. |
| US8071914B2 (en) * | 2007-12-26 | 2011-12-06 | Noboru Oshima | Heating apparatus |
| JP5222550B2 (ja) * | 2007-12-27 | 2013-06-26 | 財團法人工業技術研究院 | 徐放性組成物およびその製造方法 |
| US9161943B2 (en) | 2007-12-31 | 2015-10-20 | Industrial Technology Research Institute | Sustained release composition and manufacturing method thereof |
| CA2714514C (en) * | 2008-02-08 | 2016-08-16 | Qps Llc | Non-polymeric compositions for controlled drug delivery |
| US20100015240A1 (en) | 2008-07-16 | 2010-01-21 | Danielle Biggs | Process for preparing microparticles containing bioactive peptides |
| AU2010259184B2 (en) | 2009-06-09 | 2015-08-13 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
| CA2770149A1 (en) * | 2009-08-05 | 2011-02-10 | Pieris Ag | Controlled release formulations of lipocalin muteins |
| US20110151028A1 (en) * | 2009-12-19 | 2011-06-23 | Filiberto Zadini | Topical vaginal preparation |
| ES2362604B1 (es) * | 2009-12-22 | 2012-06-28 | Bcn Peptides, S.A. | Formulación tópica oftálmica de péptidos. |
| KR101913102B1 (ko) * | 2010-03-11 | 2018-10-31 | 와이어쓰 엘엘씨 | 메틸날트렉손의 경구 제형 및 친유성 염 |
| JP5222917B2 (ja) * | 2010-09-21 | 2013-06-26 | 財團法人工業技術研究院 | 徐放性組成物およびその製造方法 |
| TWI501781B (zh) * | 2010-12-10 | 2015-10-01 | Ind Tech Res Inst | 可控制釋放的組合物及其製造方法 |
| US20160151511A1 (en) * | 2014-12-02 | 2016-06-02 | Antriabio, Inc. | Proteins and protein conjugates with increased hydrophobicity |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US20190117573A1 (en) * | 2017-10-19 | 2019-04-25 | Hyalo Technologies, LLC | Composition and method of preparation of risperidone extended release preparation |
| US20230062487A1 (en) * | 2020-01-24 | 2023-03-02 | W. L. Gore & Associates, Inc. | Sustained-release matrices for adventitial or periadventitial neural ablation and uses thereof |
| CN111643483B (zh) * | 2020-07-06 | 2022-03-29 | 济南大学 | 一种用于制备加兰他敏缓释微球的方法 |
| US11992559B2 (en) | 2021-02-24 | 2024-05-28 | Oakwood Laboratories, Llc | Microsphere formulations comprising lurasidone and methods for making and using the same |
| EP4326237A4 (en) * | 2021-04-23 | 2025-02-26 | Flow Pharma Inc. | Microsphere formulations comprising multiple non-identical peptides and methods for making the same |
| WO2023102018A1 (en) * | 2021-12-02 | 2023-06-08 | University Of Connecticut | Long-acting injectable in situ forming biodegradable implants comprising non-steroidal anti-inflammatory drugs |
| CN116421578A (zh) * | 2023-03-31 | 2023-07-14 | 辉粒药业(苏州)有限公司 | 生长抑素类似物缓释微球及其制备方法 |
| AU2024253395A1 (en) * | 2023-04-03 | 2025-10-02 | Ferring B.V. | Methods of manufacturing peptide salts |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3664963A (en) | 1969-10-22 | 1972-05-23 | Balchem Corp | Encapsulation process |
| US3780195A (en) | 1969-10-22 | 1973-12-18 | Balchem Corp | Encapsulation process |
| DE2059494B2 (de) | 1970-12-03 | 1972-03-16 | Licentia Gmbh | Biegsamer hohlleiter |
| JPS523342B2 (cg-RX-API-DMAC7.html) | 1972-01-26 | 1977-01-27 | ||
| US3865352A (en) | 1973-11-16 | 1975-02-11 | Minnesota Mining & Mfg | Static mixing device |
| DE2604832A1 (de) | 1976-02-07 | 1977-08-11 | Basf Ag | Verfahren zur analyse von loesungen |
| US4171981A (en) | 1977-04-29 | 1979-10-23 | The Mead Corporation | Process for the production of hot melt coating compositions containing microcapsules |
| US4183681A (en) | 1978-05-19 | 1980-01-15 | Exxon Research & Engineering Co. | Emulsion preparation method using a packed tube emulsifier |
| US4299501A (en) | 1979-08-10 | 1981-11-10 | Ortho Pharmaceutical Corporation | Continuous process for the preparation of semisolid dispersions |
| US4384975A (en) | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
| US4933105A (en) | 1980-06-13 | 1990-06-12 | Sandoz Pharm. Corp. | Process for preparation of microspheres |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| DE3732370A1 (de) | 1987-09-25 | 1989-04-06 | Hoechst Ag | Verfahren zur vermischung von lebenden zellen oder mikroorganismen mit einer viskosen fluessigkeit und mischungen, die nach diesem verfahren hergestellt wurden |
| DE69024953T3 (de) | 1989-05-04 | 2005-01-27 | Southern Research Institute, Birmingham | Einkapselungsverfahren |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5112604A (en) * | 1989-09-01 | 1992-05-12 | Riker Laboratories, Inc. | Oral suspension formulation |
| MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| FR2660556B1 (fr) * | 1990-04-06 | 1994-09-16 | Rhone Poulenc Sante | Microspheres, leur procede de preparation et leur utilisation. |
| US6120805A (en) * | 1990-04-06 | 2000-09-19 | Rhone-Poulenc Rorer Sa | Microspheres, process for their preparation and their use |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| NZ260909A (en) | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
| EP1649850A1 (en) | 1993-11-19 | 2006-04-26 | Alkermes Controlled Therapeutics Inc. II | Preparation of biodegradable microparticles containing a biologically active agent |
| JP2832143B2 (ja) | 1993-12-28 | 1998-12-02 | 信越化学工業株式会社 | シリコーン微粒子およびその製造方法 |
| WO1997004747A1 (en) | 1995-07-27 | 1997-02-13 | Dunn James M | Drug delivery systems for macromolecular drugs |
| US5629277A (en) * | 1995-10-04 | 1997-05-13 | William L. Brown | Paint removing composition |
| US6140040A (en) | 1995-10-06 | 2000-10-31 | Advanced Minerals Corporation | Method of mechanically separating microparticles suspended in fluids using particulate media |
| EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
| JPH10273447A (ja) | 1997-01-29 | 1998-10-13 | Takeda Chem Ind Ltd | 徐放性マイクロスフィア、その製造法および用途 |
| AU5678398A (en) * | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
| SE9701161D0 (sv) * | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use I |
| AR012448A1 (es) | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| JP4918188B2 (ja) | 1997-12-16 | 2012-04-18 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | サブミクロンの水中油型エマルジョンと合わせた微粒子の使用 |
| SK10272000A3 (sk) | 1998-01-16 | 2001-01-18 | Takeda Chemical Industries, Ltd. | Prostriedok s trvalým uvoľňovaním, spôsob jeho výroby a jeho použitia |
| US6270700B1 (en) * | 1998-07-23 | 2001-08-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Encapsulation of water soluble peptides |
| JP3012608B1 (ja) | 1998-09-17 | 2000-02-28 | 農林水産省食品総合研究所長 | マイクロチャネル装置及び同装置を用いたエマルションの製造方法 |
| US6194006B1 (en) * | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| EP1044683A1 (en) * | 1999-04-15 | 2000-10-18 | Debio Recherche Pharmaceutique S.A. | One-step dispersion method for the microencapsulation of water soluble substances |
| US6291013B1 (en) | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
| US7919119B2 (en) | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| AU7853500A (en) | 1999-10-08 | 2001-04-23 | Procter & Gamble Company, The | Apparatus and process for in-line preparation of hipes |
| AUPQ529000A0 (en) * | 2000-01-28 | 2000-02-17 | Research Laboratories Of Australia Pty Ltd | Toner characterization cell |
| US6953593B2 (en) | 2000-02-01 | 2005-10-11 | Lipoprotein Technologies, Inc. | Sustained-release microencapsulated delivery system |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| JP2002126043A (ja) * | 2000-07-17 | 2002-05-08 | Takeda Chem Ind Ltd | 凍結乾燥物の製造法 |
| US6565873B1 (en) | 2000-10-25 | 2003-05-20 | Salvona Llc | Biodegradable bioadhesive controlled release system of nano-particles for oral care products |
| WO2002036169A2 (en) * | 2000-10-31 | 2002-05-10 | Pr Pharmaceuticals, Inc. | Methods and compositions for enhanced delivery of bioactive molecules |
| JP2004525403A (ja) | 2001-01-15 | 2004-08-19 | スリーエム イノベイティブ プロパティズ カンパニー | 可視波長領域における透過が高く、かつ平滑な多層赤外反射フィルム、およびそれから製造される積層物品 |
| CA2435415A1 (en) | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
| AR034641A1 (es) * | 2001-06-29 | 2004-03-03 | Takeda Pharmaceutical | Composicion de liberacion controlada y metodo para producirla |
| US20060083778A1 (en) | 2002-05-03 | 2006-04-20 | Dean Allison | Controlled release compositions of estradiol metabolites |
| JP2007525442A (ja) * | 2003-03-05 | 2007-09-06 | ピーアール ファーマシューティカルズ，インコーポレイテッド | オキシトシン制御放出処方物およびオキシトシン制御放出処方物を使用する方法 |
| ES2427092T3 (es) | 2003-04-10 | 2013-10-28 | Evonik Corporation | Un método para la producción de micropartículas a base de emulsión |
| US20070207211A1 (en) | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
| BRPI0409322B8 (pt) | 2003-04-11 | 2021-05-25 | Antriabio Inc | método para preparar um conjugado de insulina-polímero |
| WO2005009356A2 (en) | 2003-07-15 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Method for the preparation of controlled release formulations |
| EP2444069B1 (en) | 2003-07-23 | 2019-06-05 | Evonik Corporation | Controlled release compositions |
-
2004
- 2004-07-15 WO PCT/US2004/022816 patent/WO2005009356A2/en not_active Ceased
- 2004-07-15 BR BRPI0412059-0A patent/BRPI0412059A/pt not_active IP Right Cessation
- 2004-07-15 ES ES04778360.0T patent/ES2625343T3/es not_active Expired - Lifetime
- 2004-07-15 JP JP2006520347A patent/JP5165239B2/ja not_active Expired - Fee Related
- 2004-07-15 CA CA2532302A patent/CA2532302C/en not_active Expired - Fee Related
- 2004-07-15 EP EP04778360.0A patent/EP1651136B1/en not_active Expired - Lifetime
- 2004-07-15 CN CN200480026606.7A patent/CN1852687B/zh not_active Expired - Fee Related
- 2004-07-15 CN CN2012104691508A patent/CN102935069A/zh active Pending
- 2004-07-15 EP EP11187402A patent/EP2462896A1/en not_active Withdrawn
- 2004-07-15 AU AU2004259208A patent/AU2004259208B2/en not_active Ceased
- 2004-07-15 US US10/564,494 patent/US8871269B2/en active Active
-
2011
- 2011-04-27 JP JP2011100206A patent/JP2011144207A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011144207A5 (cg-RX-API-DMAC7.html) | ||
| AU2015342969B2 (en) | Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state | |
| Barouti et al. | Advances in drug delivery systems based on synthetic poly (hydroxybutyrate)(co) polymers | |
| AU2004259208B2 (en) | Method for the preparation of controlled release formulations | |
| CA2533592C (en) | Controlled release compositions | |
| WO2009066955A3 (en) | Lyophilized pharmaceutical composition with improved stability containing taxane derivatives, and method of manufacturing the same | |
| Ohyagi et al. | Synergetic role of hypromellose and methacrylic acid copolymer in the dissolution improvement of amorphous solid dispersions | |
| EA200870559A1 (ru) | Стабильная фармацевтическая композиция, содержащая доцетаксел, и способ изготовления таковой | |
| ITTO20000963A1 (it) | Microparticella a rilascio prolungato e metodo per la sua preparazione. | |
| KR101224004B1 (ko) | 단백질, 폴리펩타이드 또는 펩타이드 약물 전달용 고분자 및 그 제조방법, 및 단백질, 폴리펩타이드 또는 펩타이드 약물의 서방형 조성물 및 그 제조 방법 | |
| HRP20221208T1 (hr) | Depot sustav koji sadrži glatiramer acetat | |
| JP2010235584A5 (cg-RX-API-DMAC7.html) | ||
| SG176239A1 (en) | Multi-phase microparticles and method of manufacturing multi-phase microparticles | |
| JP2011225600A5 (cg-RX-API-DMAC7.html) | ||
| HK1217912A1 (en) | Controlled-released peptide formulations | |
| Dalwadi et al. | An ion pairing approach to increase the loading of hydrophilic and lipophilic drugs into PEGylated PLGA nanoparticles | |
| CN105168130B (zh) | 一种肿瘤靶向聚合物胶束及其制备方法 | |
| Zhang et al. | PTMC and MPEG-PTMC microparticles for hydrophilic drug delivery | |
| RU2016103088A (ru) | Фармацевтическое водорастворимое противогрибковое макромолекулярное соединение | |
| Ito et al. | Three-layered microcapsules as a long-term sustained release injection preparation | |
| US20230225993A1 (en) | Microsphere formulations comprising ketamine and methods for making and using the same | |
| EP3372224A1 (en) | New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles | |
| JP6357961B2 (ja) | α−ヒドロキシカルボン酸重合体材料の製造方法、および該α−ヒドロキシカルボン酸重合体材料を含有する医薬製剤 | |
| CN104352449A (zh) | 一种无突释效应的伊立替康微球及其制备方法 | |
| CN103613741A (zh) | 改变单体顺序的plga微米颗粒的制备方法 |